A new method screens large libraries of synthetic cyclic peptides to identify compounds that can enter cells for therapeutic effect.

CycPeptMPDB, a novel database created by Tokyo Tech researchers, focuses on the membrane permeability of cyclic peptides and could accelerate the development of drugs based on these promising ...

Cyclic peptides often exhibit low membrane permeability which can be significantly improved via amide-to-ester substitutions—as demonstrated by researchers from Tokyo Institute of Technology (Tokyo ...

Many diseases are driven by proteins interacting with each other inside cells. But blocking these interactions with drugs is difficult because typical "small-molecule" drugs often prove to be too ...

The MarketWatch News Department was not involved in the creation of this content. -- PEGASUS(TM) is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable ...

1910 is on a mission to “make undruggable targets a thing of the past” by “turning every pharma company into an AI company,” says founder and CEO, Jen Asher, PhD. The Sam Altman–backed AI drug ...

The effectiveness of any drug molecule depends on how well it interacts with the internal environment inside our body. Its pharmacokinetic (PK) properties determine how successfully it escapes ...

CycPeptMPDB, a novel database—created by Tokyo Tech researchers—focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds.